For the Inventor, By the Inventor

Enter assignee name

Cambridge, MA, United States of America

Cadent Therapeutics, Inc.

USPTO Granted Patents = 17

CIPO Patents = 1

EPO Patents = 6

Forward Citations = 57

Loading Chart...

Loading Chart...

26 inventors (with patents filed for the assignee):

David R Anderson (13 out of 46 patents)

Robert A Volkmann (13 out of 74 patents)

Frank S Menniti (10 out of 25 patents)

4. Gregg F Keaney (7 out of 21 patents)

5. Christopher Fanger (6 out of 29 patents)

6. Janus Schreiber Larsen (4 out of 15 patents)

7. Martin R Jefson (4 out of 19 patents)

8. Thomas Amos Jacobsen (4 out of 4 patents)

9. Steven C Leiser (3 out of 3 patents)

10. Sam Malekiani (3 out of 3 patents)

11. Timothy Piser (3 out of 7 patents)

12. Dipak Vasantrao Amrutkar (3 out of 3 patents)

13. Kelly Foster (3 out of 3 patents)

14. Karin Sandager Nielsen (3 out of 10 patents)

15. Yuelian Xu (1 out of 10 patents)

17 patents: Sort by Forward Citations

1. 11542264 - Heteroaromatic NMDA receptor modulators and uses thereof (2023-01-03),

2. 11541057 - Thienopyrimidinone NMDA receptor modulators and uses thereof (2023-01-03),

3. 11274107 - NMDA receptor modulators and uses thereof (2022-03-15),

4. 11236104 - Heteroaromatic NMDA receptor modulators and uses thereof (2022-02-01),

5. 11116749 - Selective octahydro-cyclopenta[c]pyrrole negative modulators of NR2B (2021-09-14),

6. 10973825 - Thienopyrimidinone NMDA receptor modulators and uses thereof (2021-04-13),

7. 10781174 - N-alkylaryl-5-oxyaryl-octahydro-cyclopenta[C]pyrrole negative allosteric modulators of NR2B (2020-09-22),

8. 10774064 - Potassium channel modulators (2020-09-15),

9. 10752633 - Heteroaromatic NMDA receptor modulators and uses thereof (2020-08-25),

10. 10717728 - Potassium channel modulators (2020-07-21),

11. 10626122 - Heteroaromatic NMDA receptor modulators and uses thereof (2020-04-21),

12. 10584131 - Heteroaromatic NMDA receptor modulators and uses thereof (2020-03-10),

13. 10500205 - Thienopyrimidinone NMDA receptor modulators and uses thereof (2019-12-10),

14. 10351553 - Potassium channel modulators (2019-07-16),

15. 10239835 - N-alkylaryl-5-oxyaryl-octahydro-cyclopenta[c]pyrrole negative allosteric modulators of NR2B (2019-03-26),

Cadent Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel therapies for the treatment of movement disorders. The company's mission is to harness breakthrough scientific insights in the areas of synaptic plasticity and aberrant neuronal signaling to create transformative medicines. Cadent Therapeutics aims to bring innovative treatments to patients with movement disorders such as Parkinson's disease, essential tremor, and dystonia.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Jan 6 2026

17 Patents

#129 in Cambridge, MA

#1,108 in Massachusetts

#18,344 in US

#34,876 in the World

Cambridge, MA, United States of America

Cadent Therapeutics, Inc.

Forward Citations = 57

26 inventors:

David R Anderson (13 out of 46 patents)

Robert A Volkmann (13 out of 74 patents)

Frank S Menniti (10 out of 25 patents)

4. Gregg F Keaney (7 out of 21 patents)

5. Christopher Fanger (6 out of 29 patents)

Please report any incorrect information to support@idiyas.com

Loading…